Gilead Sciences ( GILD) said its first-quarter revenue surged 22% from a year earlier as product sales reached a record high of $1.45 billion.

The Foster City, Calif., biotechnology company had total revenue of $1.53 billion, up from $1.26 billion a year ago. Gilead earned $589.1 million, or 63 cents a share, including after-tax stock-based compensation expenses of $30.3 million, compared with earnings of $488.3 million and 51 cents a share last year.

Before items, the company would have earned 66 cents. Analysts were calling for a profit of 59 cents and revenue of $1.50 billion.

Product sales, meanwhile, rose 27% from $1.14 billion in the first quarter of 2008, mainly because of antiviral drugs. The HIV fighters Atripla and Truvada saw their sales increase 57% and 23%, respectively. Truvada's sales totaled $590.4 million, and revenue from Atripla reached $509.9 million.

Sales of Letairis, a treatment for pulmonary arterial hypertension, nearly doubled to $39.6 million.

Gilead's shares slipped 4 cents to $43.73 in the regular session, but the stock climbed $1.67, or 3.8%, to $45.40 in late trading.

The coming days will see more reports from the biotech sector, including Elan ( ELN), Genzyme ( GENZ) and Amgen ( AMGN).

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside